Search Within

Anas Younes

Formats
  1. Meeting Abstract (153)
  2. Journal Article (136)
  3. Book Section (13)
  4. Book Whole (4)
  5. Editorial (4)
  6. Review (4)
  7. Conference Paper (2)
  8. Research Letter (2)
  9. Correspondence (1)
  10. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (320)
  2. Department of Medicine (320)
  3. Executive Committee, Center for Hematologic Malignancies (320)
  4. Hematologic Malignancies, Division of (320)
  5. Lymphoma (320)
  6. Epidemiology and Biostatistics (82)

More Groups

People
  1. Andrew Zelenetz (89)
  2. Connie Batlevi (81)
  3. David Straus (74)
  4. Matthew Matasar (68)
  5. Anita Kumar (67)
  6. Paul Hamlin (67)

More People

Years
  1. 2024 (3)
  2. 2023 (7)
  3. 2022 (11)
  4. 2021 (13)
  5. 2020 (26)
  6. 2019 (53)

More Years

Publications
  1. Blood (91)
  2. Journal of Clinical Oncology (25)
  3. Hematological Oncology (22)
  4. Haematologica (16)
  5. British Journal of Haematology (13)
  6. Cancer Research (10)

More Publications

Publishers
  1. American Society of Hematology (99)
  2. American Society of Clinical Oncology (27)
  3. Wiley Blackwell (25)
  4. Nature Publishing Group (19)
  5. Springer (17)
  6. American Association for Cancer Research (16)

More Publishers

Results (320)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Dose finding study to assess safety, PK and efficacy of fimepinostat (CUDC‐907) with venetoclax or rituximab plus bendamustine in patients with relapsed/refractory lymphoma
    Meeting Abstract

    Younes, A.; Batlevi, C. L.; Cohen, J. B.; Kelly, K.; Landsburg, D. J.; Patel, K.; Phillips, T.; Smith, S.; Westin, J.; Ma, A. W.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Safety and early data from a phase II trial of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (Hl) and follicular lymphoma (FL)
    Meeting Abstract

    Sermer, D.; Vardhana, S.; Batlevi, C.; Hamilton, A.; Moskowitz, A.; Caron, P.; Moskowitz, C.; Matasar, M.; Biggar, E.; Leung, E.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical significance and outcomes in patients with diffuse large B‐cell lymphoma (DLBCL) harboring extra copies [EC] and/or translocations [TL] of MYC, BCL2, and BCL6
    Meeting Abstract

    Sermer, D.; Bobillo, S.; Seshan, V.; Dogan, A.; Younes, A.
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Exploratory biomarker analysis in the PH 3 ECHELON‐1 study: Worse outcome with ABVD in patients with elevated baseline levels of SCD30 and TARC
    Meeting Abstract

    Radford, J.; Connors, J. M.; Younes, A.; Gallamini, A.; Ansell, S. M.; Kim, W. S.; Cheong, J.; Flinn, I.; Kalakonda, N.; Kaminski, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Incidence and treatment outcomes of patients with transformed marginal zone lymphoma treated with RCHOP‐like regimens
    Meeting Abstract

    Rajeeve, S.; Bobillo, S. V.; Zelenetz, A. D.; Straus, D. J.; Palomba, M. L.; Noy, A.; Horwitz, S. M.; Moskowitz, A. J.; Hamlin, P. A.; Matasar, M. J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Clinical characteristics and outcomes of stage I diffuse large B cell lymphoma (DLBCL) in the rituximab‐era
    Meeting Abstract

    Bobillo, S.; Joffe, E.; Lavery, J.; Noy, A.; Palomba, L.; Straus, D. J.; Kumar, A.; Batlevi, C.; Horwitz, S.; Moskowitz, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Phase I clinical trial of CD19‐targeted 19‐28z/4‐1BBL "armored" CAR T cells in patients with relapsed or refractory NHL and CLL including Richter transformation
    Meeting Abstract

    Batlevi, C. L.; Palomba, M. L.; Park, J.; Mead, E.; Santomasso, B.; Riviere, I.; Wang, X.; Senechal, B.; Furman, R.; Yang, J.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • EZH2 gain‐of‐function mutations are not associated with more favorable prognosis in relapsed/refractory follicular lymphoma (FL): A preliminary analysis on 590 patients
    Meeting Abstract

    Okosun, J.; Bödör, C.; Batlevi, C.; Nagy, N.; Michot, J.; Schneider, T.; Alizadeh, H.; Simon, Z.; Vose, J.; Younes, A.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Concordance between immunohistochemistry and gene expression profiling subtyping for diffuse large B‐cell lymphoma in the phase 3 PHOENIX trial
    Meeting Abstract

    Balasubramanian, S.; Wang, S.; Major, C.; Hodkinson, B.; Schaffer, M.; Sehn, L. H.; Johnson, P.; Zinzani, P. L.; Carey, J.; Liu, G.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save
  • Impact of pet imaging and histologic transformation on the prognosis of early disease progression in follicular lymphoma
    Meeting Abstract

    Batlevi, C. L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S. M.; Kumar, A.; Matasar, M.; more...
    Hematological Oncology (2019)

    Fulltext@MSK | Save